Aligos Therapeutics (STU:5WK0) FFO


STU:5WK0 Aligos Therapeutics Inc STU:5WK0
26 GF Score
Price €5.14
GF Value €2.40
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:5WK0
26GF Score
Aligos Therapeutics Inc STU:5WK0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of €5.14 is trading 114.2% above its estimated GF Value™ of €2.40. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:5WK0:

  • FFO:
  • GF Value™: €2.40 vs. price of €5.14 (114.2% above fair value)
  • GF Score™: 26/100 with 4 warning signs

No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aligos Therapeutics Business Description

Other Exchanges ALGS:USA
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
26GF Score

Get the complete analysis for STU:5WK0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.14
Price
€2.40
GF Value